PEEL-224
- Generic Name
- PEEL-224
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Phase 1
Recruiting
- Conditions
- Refractory Solid TumorsRelapsed Solid TumorsRelapsed NeuroblastomaRefractory NeuroblastomaRelapsed RhabdomyosarcomaRefractory Rhabdomyosarcoma
- Interventions
- First Posted Date
- 2024-12-06
- Last Posted Date
- 2025-03-26
- Lead Sponsor
- Theodore Laetsch
- Target Recruit Count
- 59
- Registration Number
- NCT06721689
- Locations
- ๐บ๐ธ
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination with Vincristine and Temozolomide in Adolescents and Young Adults with Relapsed or Refractory Sarcomas
Phase 1
Recruiting
- Conditions
- SarcomaSarcoma, EwingOsteosarcomaRhabdomyosarcomaDesmoplastic Small Round Cell TumorRefractory Sarcoma
- Interventions
- First Posted Date
- 2024-11-29
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- David S Shulman, MD
- Target Recruit Count
- 63
- Registration Number
- NCT06709495
- Locations
- ๐บ๐ธ
Boston Children's Hospital, Boston, Massachusetts, United States
๐บ๐ธDana-Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธBrigham and Women's Hospital, Boston, Massachusetts, United States
A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Peel Therapeutics Inc
- Target Recruit Count
- 42
- Registration Number
- NCT05329103
- Locations
- ๐บ๐ธ
HonorHealth Research Institiute, Scottsdale, Arizona, United States
๐บ๐ธStanford Cancer Center, Palo Alto, California, United States
๐บ๐ธCarolina BioOncology Institute, Huntersville, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2025. All Rights Reserved by MedPath